

Role of Amyloid Beta and Tau Protein in Alzheimer's disease

Rajkumari Lodhi, Virendra Kumar Sharma*

School of Pharmacy, LNCT University, Bhopal, Madhya Pradesh, INDIA.

ABSTRACT

Alzheimer's disease is the leading cause of dementia and represents the most prevalent neurodegenerative condition worldwide. It is characterized by progressive deterioration in short-term memory and cognitive abilities, eventually interfering with everyday activities and behavior. Although most cases occur sporadically, a smaller proportion is inherited, enabling the identification of specific genes that, along with neuropathological findings, provide valuable insight into the broader origins of the disease. A variety of environmental and metabolic influences, such as inflammation and vascular dysfunction, are also believed to contribute to the initiation and advancement of the disorder. Despite widespread neuronal shrinkage and synaptic loss across the cerebral cortex, the precise mechanisms responsible for these changes are still not fully understood. The primary pathological features associated with Alzheimer's disease are amyloid- β plaques and neurofibrillary tau tangles. Although these protein accumulations have been intensively studied for decades, their exact contribution to disease progression remains uncertain. This review explores several proposed mechanisms involved in Alzheimer's disease, including inflammation, mitochondrial impairment, oxidative stress, and disruptions in protein clearance pathways.

Keywords: Amyloid- β plaques, Alzheimer's disease Etiology, Dementia, Neurodegeneration, Neurofibrillary Tau Tangles.

Correspondence:

Dr. Virendra Kumar Sharma

School of Pharmacy, LNCT University,
Bhopal, Madhya Pradesh INDIA.
Email: dr.virendra48@gmail.com

Received: 16-02-2026;

Revised: 09-04-2026;

Accepted: 23-06-2026.

INTRODUCTION

Alzheimer's disease

Alzheimer's disease (AD) is a chronic and progressive neurodegenerative condition that is recognized as one of the leading causes of dementia across the globe. The prevalence of the disease continues to rise, particularly among older adults. Reports from the United States estimate that approximately 5.4 million individuals of different age groups have been affected, and the number is expected to increase considerably in the coming decades (Alzheimer's Association, 2016; Brooks, 2012; Hardy and Allsop, 1991; Selkoe and Hardy, 2016).

AD is associated with a gradual deterioration of cognitive abilities, behavioral and personality alterations, neuronal degeneration, synaptic dysfunction, formation of senile plaques, and neurofibrillary tangles. The disease is considered multifactorial in nature, arising from both genetic and environmental influences. Genetic mutations account for fewer than 5% of cases and are mainly linked to early-onset or familial Alzheimer's disease.

Mutations in genes such as Amyloid Precursor Protein (APP), Presenilin 1 (PSEN1), and Presenilin 2 (PSEN2) are strongly implicated in the development of familial forms of the disorder. In contrast, sporadic cases are more commonly associated with nongenetic factors, including metabolic abnormalities and environmental influences (Hardy and Allsop, 1991; Reiman *et al.*, 2020; Tanzi and Bertram, 2005).

Alzheimer's disease late-onset or Sporadic Alzheimer's Disease (SAD) is strongly influenced by factors such as inflammation, oxidative stress, and metabolic dysfunction. In addition, alterations in the APOE gene have been widely associated with an increased risk of developing sporadic forms of the disease. Over the past several decades, extensive research has focused on understanding the underlying mechanisms and identifying effective therapeutic approaches for AD; however, its precise cause remains incompletely understood (Hardy and Selkoe, 2002; Selkoe and Hardy, 2016).

To explain the onset and progression of AD, several hypotheses have been proposed, among which the amyloid hypothesis is one of the most prominent. Current evidence suggests that the excessive accumulation of Amyloid-Beta ($A\beta$) peptides, the formation of neurofibrillary tangles caused by hyper phosphorylated Tau protein, cholinergic system impairment, neuroinflammation, oxidative stress, metabolic abnormalities, and disrupted cerebral energy metabolism all contribute to neuronal degeneration in AD (Kivipelto *et al.*, 2008).



DOI: 10.5530/jpccm.20260040

Copyright Information :

Copyright Author (s) 2026 Distributed under
Creative Commons CC-BY 4.0

Publishing Partner : Manuscript Technomedia, [www.mstechnomedia.com]

At present, the approved pharmacological treatments for AD mainly include acetylcholinesterase inhibitors such as donepezil and rivastigmine, along with N-Methyl-D-Aspartate Receptor (NMDAR) antagonists. Although these medications can temporarily improve symptoms, they do not effectively halt or reverse disease progression (Holtzman, Herz, and Bu, 2012; Mattson, 2004; Winblad *et al.*, 2016).

Despite considerable advances in understanding the biological and clinical features of AD and identifying numerous risk factors, therapies capable of slowing or preventing disease progression remain limited. This challenge has emphasized the importance of developing reliable experimental models that closely mimic the pathological and clinical characteristics of AD. Over the years, a wide variety of animal models have been established, ranging from short-lived organisms such as worms to long-living mammals, including transgenic models that successfully reproduce many AD-related features (Gandy and Tanzi, 2010; LaFerla and Oddo, 2005). However, translating findings from preclinical animal studies into successful clinical treatments continues to be difficult. Moreover, animal-based research often requires substantial time, labor, and resources, creating additional barriers to efficient drug discovery.

Consequently, current research increasingly focuses on alternative approaches, including advanced *in vitro* systems, *in silico* modeling, and pluripotent stem cell technologies, which may provide improved platforms for understanding disease mechanisms and developing future therapeutics for Alzheimer's disease (Borchelt *et al.*, 1996; Suci and Huang, 2021).

Pathophysiology of Alzheimer's disease

AD is a chronic, progressive, and irreversible neurodegenerative disorder that primarily affects memory, cognition, behavior, and functional abilities. It is recognized as the most common cause of dementia among elderly individuals worldwide. The pathophysiology of Alzheimer's disease is highly complex and multifactorial, involving a combination of genetic, biochemical, molecular, and environmental factors that collectively contribute to neuronal dysfunction and progressive brain degeneration. Although extensive research has been conducted over the past several decades, the exact mechanisms responsible for the initiation and progression of AD are still not fully understood. Nevertheless, several characteristic pathological features and mechanistic hypotheses have been identified that explain the disease process to a significant extent.

The hallmark pathological changes observed in Alzheimer's disease include extracellular deposition of Amyloid-beta ($A\beta$) plaques, intracellular formation of Neurofibrillary Tangles (NFTs) composed of hyperphosphorylated Tau protein, synaptic dysfunction, progressive neuronal loss, mitochondrial abnormalities, oxidative stress, excitotoxicity, vascular impairment, and chronic neuroinflammation. These pathological

alterations gradually impair neuronal communication and ultimately lead to widespread brain atrophy, especially in regions associated with learning and memory such as the hippocampus and cerebral cortex. The cumulative effect of these changes results in progressive cognitive decline and behavioral abnormalities characteristic of AD.

One of the earliest explanations proposed for the pathogenesis of Alzheimer's disease was the cholinergic hypothesis, which emerged during the 1970s. According to this theory, the primary cause of cognitive deterioration in AD patients is the deficiency of the neurotransmitter acetylcholine, which plays a crucial role in memory formation, attention, learning, and other higher cognitive processes. In AD, degeneration of cholinergic neurones occurs predominantly in the basal forebrain, particularly within the nucleus basalis of Meynert, leading to reduced cholinergic transmission in the cerebral cortex and hippocampus. This neurotransmitter deficit was believed to contribute significantly to memory impairment and cognitive dysfunction observed in affected individuals (DeTure and Dickson, 2019; Kumar *et al.*, 2015).

The cholinergic hypothesis gained considerable attention because it provided the foundation for the development of therapeutic agents aimed at enhancing cholinergic neurotransmission. As a result, acetylcholinesterase inhibitors such as donepezil, rivastigmine, and galantamine were developed and remain widely used for symptomatic treatment of Alzheimer's disease. These drugs act by inhibiting the enzyme acetylcholinesterase responsible for the breakdown of acetylcholine, thereby increasing the availability of ACh at synaptic junctions. Although these medications can temporarily improve cognitive function and delay symptom progression in some patients, they do not halt neuronal degeneration or cure the disease. Consequently, researchers recognized that additional pathological mechanisms must also be involved in AD progression.

Subsequently, the amyloid cascade hypothesis became one of the most influential and widely accepted theories explaining Alzheimer's disease pathogenesis. This hypothesis proposes that abnormal metabolism and processing of APP initiate the pathological cascade leading to neurodegeneration. APP is a transmembrane protein normally present in neuronal cells and can undergo cleavage through different enzymatic pathways. In Alzheimer's disease, APP is abnormally cleaved by β -secretase and γ -secretase enzymes, resulting in the formation of amyloid-beta peptides, particularly the highly aggregation-prone $A\beta_{42}$ isoform (DeTure and Dickson, 2019).

These amyloid-beta peptides accumulate progressively in the extracellular spaces of the brain, where they aggregate into oligomers, fibrils, and eventually insoluble amyloid plaques. The accumulation of $A\beta$ plaques interferes with synaptic communication, disrupts neuronal signaling, induces oxidative

stress, alters calcium homeostasis, damages cell membranes, and activates microglial cells and inflammatory pathways. Soluble A β oligomers are considered especially neurotoxic because they impair synaptic plasticity and contribute directly to memory dysfunction. Over time, chronic amyloid toxicity leads to neuronal injury and cell death, thereby contributing to progressive cognitive decline.

Strong genetic evidence supports the amyloid hypothesis. Mutations in genes encoding APP, Presenilin-1 (PSEN1), and Presenilin-2 (PSEN2) have been identified in familial early-onset Alzheimer's disease. These mutations increase the production or aggregation tendency of amyloid-beta peptides, particularly A β 42, thereby accelerating plaque formation and disease progression. Additionally, individuals with Down's syndrome, who possess an extra copy of Chromosome 21 containing the APP gene, frequently develop Alzheimer-like pathology at an earlier age, further supporting the role of amyloid accumulation in AD pathogenesis.

Despite substantial evidence supporting the amyloid hypothesis, several limitations and controversies remain. Some individuals exhibit significant amyloid plaque accumulation without severe cognitive impairment, whereas others demonstrate extensive neurodegeneration with relatively low plaque burden. Furthermore, many anti-amyloid therapeutic agents have shown limited clinical success in preventing or reversing cognitive decline. These observations suggest that amyloid deposition alone may not fully explain the complexity of Alzheimer's disease and that additional pathological processes such as tau pathology, neuroinflammation, mitochondrial dysfunction, vascular changes, and synaptic degeneration also play crucial roles in disease progression (Hardy and Selkoe, 2002).

Another major pathological feature of Alzheimer's disease involves the formation of neurofibrillary tangles composed of abnormally hyper phosphorylated Tau protein. Under normal physiological conditions, Tau protein stabilizes microtubules within neurones and maintains axonal transport. However, in AD, tau undergoes abnormal hyper phosphorylation, causing it to detach from microtubules and aggregate into paired helical filaments that form intracellular neurofibrillary tangles. These tangles disrupt neuronal transport systems, impair synaptic function, and ultimately lead to neuronal death. The severity of tau pathology has been found to correlate more closely with cognitive decline than amyloid plaque burden, highlighting its significant contribution to disease progression.

In addition to amyloid and tau pathology, oxidative stress and mitochondrial dysfunction are important contributors to neuronal degeneration in Alzheimer's disease. Increased production of reactive oxygen species damages lipids, proteins, nucleic acids, and cellular organelles, thereby impairing neuronal survival. Mitochondrial dysfunction further reduces cellular

energy production and enhances oxidative injury, promoting apoptosis and neurodegeneration. Chronic neuroinflammation mediated by activated microglia and astrocytes also contributes significantly to neuronal damage through the release of proinflammatory cytokines, chemokines, and neurotoxic substances (Querfurth and LaFerla, 2010).

Overall, the pathophysiology of Alzheimer's disease involves a complex interplay among amyloid-beta accumulation, tau hyper phosphorylation, cholinergic dysfunction, oxidative stress, mitochondrial impairment, synaptic degeneration, and neuroinflammatory processes. These interconnected mechanisms progressively damage neuronal networks and ultimately result in the characteristic cognitive and behavioral impairments associated with the disease. Continued research into these pathological pathways is essential for the development of more effective disease-modifying therapies aimed at preventing or slowing the progression of Alzheimer's disease (Lane *et al.*, 2018).

Amyloid hypothesis

Amyloid hypothesis

The amyloid hypothesis is one of the most widely accepted and extensively studied theories explaining the pathogenesis of AD. This hypothesis proposes that abnormal production, accumulation, and aggregation of Amyloid-beta (A β) peptides within the brain represent the primary pathological events that initiate a cascade of neurodegenerative processes leading to Alzheimer's disease. According to this concept, excessive deposition of A β peptides contributes to synaptic dysfunction, neuronal injury, tau pathology, neuroinflammation, and ultimately progressive cognitive decline.

Amyloid-beta (A β) peptides are small hydrophobic peptide fragments consisting of approximately 39-43-aa residues. Among the various isoforms, A β 40 and A β 42 are the most predominant and biologically significant forms. A β 42, in particular, is considered highly pathogenic because of its greater hydrophobicity and tendency to aggregate rapidly into oligomers and fibrils. Numerous experimental, genetic, and clinical studies have demonstrated that both A β 40 and A β 42 play important roles in neuronal degeneration and impairment of cognitive functions. These peptides are capable of triggering a series of pathological events including oxidative stress, synaptic dysfunction, mitochondrial damage, neuroinflammation, and tau hyperphosphorylation, eventually resulting in neuronal death (Hardy and Higgins, 1992).

The concept of amyloid involvement in Alzheimer's disease emerged following the identification and isolation of amyloid-like proteins from senile plaques and meningeal blood vessels of AD patients. Similar pathological deposits were also observed in individuals with Down's syndrome, who commonly develop early-onset Alzheimer-like dementia. This observation suggested a possible association between amyloid deposition and

neurodegeneration. Further support for the hypothesis came with the discovery of APP, a transmembrane glycoprotein responsible for generating amyloid-beta peptides. Identification of APP and its genetic association with familial Alzheimer's disease strongly reinforced the idea that abnormal amyloid metabolism plays a central role in AD pathogenesis (Selkoe and Hardy, 2016).

The amyloid hypothesis postulates that excessive production or impaired clearance of A β peptides leads to their abnormal accumulation either intracellularly or extracellularly in the brain. These peptides may exist in several forms including soluble monomers, soluble oligomers, insoluble fibrils, and extracellular amyloid plaques. Among these, soluble A β oligomers are considered particularly neurotoxic because they interfere with synaptic signaling and impair neuronal plasticity even before plaque formation becomes evident. Progressive accumulation of A β ultimately promotes the formation of neuritic plaques and cerebral amyloid angiopathy, both of which are characteristic pathological hallmarks of Alzheimer's disease (Kumar *et al.*, 2015).

Amyloid-beta peptides are generated through the proteolytic processing of APP. APP can undergo two major metabolic pathways: the nonamyloidogenic pathway and the amyloidogenic pathway. Under normal physiological conditions, APP is predominantly processed through the nonamyloidogenic pathway, which prevents the formation of A β peptides. In this pathway, APP is initially cleaved by α -secretase, an enzyme belonging mainly to the disintegrin and metalloprotease family, particularly ADAM10. α -secretase cleaves APP within the A β region, thereby preventing amyloid-beta formation and releasing a soluble extracellular fragment known as sAPP α , which possesses neuroprotective properties.

In contrast, the amyloidogenic pathway leads to the production of amyloid-beta peptides and is considered central to Alzheimer's disease pathology. In this pathway, APP undergoes sequential proteolytic cleavage by two major enzymes: β -secretase and γ -secretase. Initially, β -secretase, also known as β -site APP cleaving Enzyme-1 (BACE1), cleaves APP at the N-terminal region of the A β domain. This cleavage generates a soluble extracellular fragment termed sAPP β and a membrane-bound C-terminal fragment consisting of 99-aa residues, commonly referred to as CTF99 or C99.

Subsequently, the C99 fragment is further cleaved by the γ -secretase complex, a multisubunit enzyme complex composed of presenilin-1 or presenilin-2, nicastrin, anterior pharynx-defective-1, and presenilin Enhancer-2. Among these components, PS1 and PS2 form the catalytic core of the complex. γ -secretase-mediated cleavage results in the generation of different A β isoforms, predominantly A β 40 and A β 42. Although A β 40 is produced in larger quantities, A β 42 is more aggregation-prone

and exhibits greater neurotoxicity, making it more strongly associated with Alzheimer's disease progression (Querfurth and LaFerla, 2010).

Accumulated A β peptides aggregate to form oligomers, protofibrils, fibrils, and ultimately extracellular amyloid plaques within the brain parenchyma. These aggregates disrupt neuronal communication, impair synaptic transmission, alter calcium homeostasis, induce oxidative stress, and activate microglial-mediated inflammatory responses. Chronic amyloid accumulation also contributes to tau hyperphosphorylation and neurofibrillary tangle formation, thereby linking amyloid pathology with other major pathological features of Alzheimer's disease.

Genetic studies provide strong evidence supporting the amyloid hypothesis. Mutations in APP, Presenilin-1 (PSEN1), and Presenilin-2 (PSEN2) genes are associated with familial early-onset Alzheimer's disease and lead to increased production or altered processing of A β 42 peptides. Furthermore, individuals with trisomy 21 (Down's syndrome), who possess an extra copy of the APP gene located on Chromosome 21, frequently exhibit early amyloid deposition and Alzheimer-like neuropathology.

Despite extensive evidence supporting the amyloid hypothesis, certain limitations and controversies remain. Some patients exhibit significant amyloid plaque deposition without severe cognitive impairment, while others show cognitive decline with relatively low amyloid burden. In addition, several anti-amyloid therapies have demonstrated limited success in clinical trials. These findings suggest that although amyloid-beta accumulation is a critical factor in AD pathogenesis, it may act in conjunction with other mechanisms such as tau pathology, neuroinflammation, mitochondrial dysfunction, oxidative stress, and vascular abnormalities.

Overall, the amyloid hypothesis remains a fundamental framework for understanding Alzheimer's disease and has significantly influenced the development of diagnostic biomarkers and therapeutic strategies targeting amyloid-beta production, aggregation, and clearance (De and Karran, 2016) (Figure 1).

The nonamyloidogenic pathway involves the enzymatic cleavage of APP by α -secretase within the ectodomain region, thereby preventing the generation of Amyloid- β (A β) peptides. This cleavage releases a large soluble N-terminal fragment known as soluble APP- α (sAPP α), which possesses significant neuroprotective and neurotrophic activities. Simultaneously, a membrane-bound C-Terminal Fragment Termed C83 (CTFa) is produced. The C83 fragment subsequently undergoes proteolytic processing by γ -secretase, resulting in the formation of the p3 peptide (A β 17-40/42), which exhibits considerably lower neurotoxicity compared to full-length A β peptides (Alberts *et al.*, 2015).




Figure 1: Amyloid cascade.

In contrast, A β peptides generated through the amyloidogenic pathway tend to aggregate into oligomers and protofibrils characterized by β -sheet-rich secondary structures and reverse-turn conformations. These protofibrils are highly neurotoxic and progressively develop into mature fibrils and insoluble linear filaments that accumulate as amyloid plaques within specific brain regions. The deposition of amyloid plaques is considered a hallmark pathological feature of AD and can be histologically identified using Congo red staining (Kandel *et al.*, 2013).

Defensive-Clearance Hypothesis: A β Degradation

According to the amyloid cascade hypothesis, A β peptides are continuously produced through proteolytic processing of APP and subsequently accumulate in various regions of the brain. Under physiological conditions, however, A β levels are tightly regulated through degradation by a group of enzymes collectively known as A β -Degrading Proteases (A β DPs). These enzymes maintain a dynamic balance between A β production and clearance. Therefore, elevated A β accumulation in AD may result not only from increased peptide production but also from impaired degradation and clearance mechanisms. This concept is supported by findings in SAD, where reduced clearance of A β from cerebrospinal fluid has been observed (Selkoe and Hardy, 2016).

A β -degrading proteases, including various proteinases and peptidases, are localized within distinct subcellular compartments and brain regions. Depending on their localization and enzymatic specificity, these proteases generate different peptide fragments with varying degrees of pathogenic potential. Based on their functions under normal and disease conditions, A β DPs are broadly classified into endogenous regulators, which contribute to physiological A β homeostasis, and pathogenic regulators, which are associated with altered A β metabolism during disease progression (De Strooper and Karran, 2016).

Based on cholinergic hypothesis

According to the cholinergic hypothesis, impairment of cholinergic neurotransmission is considered one of the principal causes of cognitive decline and dementia in AD. Early therapeutic strategies for AD primarily targeted the cholinergic system, leading to the development of cholinesterase inhibitors such as tacrine, donepezil, rivastigmine, and galantamine, all of which received approval from the United States Food and Drug Administration for the management of AD symptoms. Subsequent advancements introduced Memogain, an inactive prodrug of galantamine that demonstrated approximately 3-5 times greater potency and nearly 15-fold enhanced bioavailability compared with its parent compound (Terry and Buccafusco, 2003).

In recent years, $\alpha 7$ nicotinic acetylcholine receptor ($\alpha 7$ nAChR) agonists have emerged as promising therapeutic candidates for symptomatic management of AD. Activation of these receptors enhances calcium influx and stimulates intracellular signaling pathways, thereby promoting the release of neurotransmitters including glutamate and γ -aminobutyric acid. Investigational agents such as Encenicline and ABT-126 have shown fewer adverse effects compared with conventional acetylcholinesterase inhibitors and are being evaluated in clinical trials for their therapeutic potential in AD (Anand and Singh, 2013).

Apart from cholinergic dysfunction, glutamatergic signaling has also been strongly implicated in AD pathogenesis, particularly through NMDARs, which are ligand-gated cation channels involved in excitatory neurotransmission, synaptic plasticity, and cognition. Binding of glutamate to NMDARs contributes to learning and memory processes; however, amyloid- β (A β) peptides can excessively activate these receptors, leading to glutamatergic dysregulation, neuronal toxicity, and abnormal intracellular calcium accumulation (Cummings *et al.*, 2021). A β -mediated alterations may also disrupt endocytosis and modify the function of AMPA and kainate receptors, thereby exacerbating neuronal damage. These findings encouraged the development of NMDAR

antagonists aimed at reducing A β -induced neurotoxicity. Memantine, a noncompetitive NMDAR antagonist, is currently used in patients with moderate to severe AD, while several newer NMDAR antagonists continue to be explored in clinical studies (Hynd *et al.*, 2004; Parsons *et al.*, 2013).

Based on A β hypothesis

The amyloid- β (A β) hypothesis emerged after the discovery of mutations in the APP gene and presenilin genes, which encode important subunits of the γ -secretase complex involved in APP cleavage. These findings suggested that excessive production and aggregation of A β peptides through the amyloidogenic pathway represent a central mechanism in the pathogenesis of AD. Consequently, β -secretase and γ -secretase became important therapeutic targets because inhibition of these enzymes could potentially decrease A β generation (Hardy and Allsop, 1991).

Amyloid hypothesis proposes that γ -secretase, a multisubunit aspartyl protease complex, is responsible for the final cleavage of APP that leads to A β formation. Experimental studies in transgenic mouse models such as PDAPP and Tg2576 demonstrated that γ -secretase inhibitors significantly lowered A β levels, encouraging the development of several γ -Secretase Inhibitors (GSIs). However, the structural complexity and heterogeneity of γ -secretase complicated the identification of selective inhibitors. In addition to APP, γ -secretase also processes nearly 50 other type-I transmembrane proteins, making selective targeting extremely difficult (Goate *et al.*, 1991; Haass and Selkoe, 2007).

One of the most important substrates of γ -secretase is the Notch signaling pathway receptor, which regulates cellular differentiation, synaptic plasticity, neuronal survival, and tumor suppression. Inhibition of Notch processing by nonselective GSIs caused severe adverse effects, including gastrointestinal toxicity and immunosuppression (De Strooper, 2003). Due to these target-related toxicities, the clinical development of several GSIs, including semagacestat and avagacestat, was discontinued despite their ability to reduce A β levels. To overcome these limitations, researchers developed Notch-sparing γ -secretase inhibitors such as BMS-708163, which demonstrated promising reductions of A β concentrations in cerebrospinal fluid and plasma with reduced toxicity (Ghosh and Osswald, 2014).

Following the limited success of GSIs, attention shifted toward β -secretase, also known as β -site APP cleaving Enzyme-1 (BACE-1). BACE-1 is a type-I transmembrane aspartyl protease belonging to the pepsin family and plays a crucial role in the initial proteolytic cleavage of APP during the amyloidogenic pathway. The enzyme contains two catalytic aspartate motifs that form its active site. Another related enzyme, BACE-2, shares approximately 64% amino acid similarity with BACE-1; however, it has not been shown to significantly contribute to

A β production. Multiple generations of peptide and nonpeptide BACE-1 inhibitors have therefore been designed and evaluated in both preclinical and clinical studies as potential anti-Alzheimer agents (Vassar *et al.*, 2014).

APP processing is considered a critical event in AD progression because the mode of APP cleavage determines whether toxic or nontoxic products are formed. In the nonamyloidogenic pathway, APP is cleaved by α -secretase, resulting in the release of soluble APP α (sAPP α), a nontoxic fragment with neuroprotective properties. Since α -secretase cleavage prevents A β formation, enhancement of α -secretase activity has been explored as an alternative therapeutic strategy for AD. Members of the disintegrin and metalloprotease family are primarily responsible for α -secretase activity. Although selective α -secretase activators are still under investigation, stimulation of α -secretase-associated signaling pathways has shown beneficial effects, including neuroprotection and reduced A β accumulation.

In addition, impaired clearance of A β has been observed in SAD, indicating that defective degradation and removal of A β peptides may also contribute significantly to disease progression (Postina, 2012).

A β degradation and immunotherapeutic approaches in Alzheimer's disease. Enhancement of A β DPs is considered equally important as reducing A β production in the treatment of AD. A β -degrading proteases act on both soluble A β monomers and, to some extent, fibrillar A β aggregates, thereby reducing amyloid burden in the brain. These observations have encouraged the development of pharmacological strategies aimed at increasing the expression or activity of A β -degrading proteases while simultaneously inhibiting endogenous molecules that suppress their function (Miners *et al.*, 2011).

Several experimental studies have demonstrated the therapeutic significance of A β degradation pathways. Increased expression of cathepsin B in animal models showed beneficial effects through enhanced degradation and clearance of A β peptides. Similarly, inhibition of cystatin C, an endogenous inhibitor of A β -degrading enzymes, was associated with neuroprotective effects and increased A β clearance. These findings suggest that modulation of A β DPs may represent a promising therapeutic strategy for limiting amyloid accumulation in AD. In addition to enzyme-based approaches, gene therapy and immunotherapy have also been explored to improve A β clearance and potentially slow disease progression (Hook *et al.*, 2008).

Among emerging therapeutic strategies, immunotherapy has attracted considerable attention because of its encouraging outcomes in animal models and clinical studies. Early landmark investigations by Dale Schenk and colleagues demonstrated that immunization of PDAPP transgenic mice with fibrillar A β 42 significantly reduced amyloid plaque formation and slowed the progression of amyloid pathology in both young and older

animals. These promising findings initiated extensive research into immunotherapeutic interventions for AD (Levy *et al.*, 2001).

Immunotherapy for AD mainly includes two approaches: active immunization and passive immunization. Active immunization involves vaccination to stimulate the body's immune response against A β , whereas passive immunization uses externally administered monoclonal antibodies directed against A β peptides. Studies in transgenic mouse models indicated that anti-A β immunization could reduce synaptic degeneration, enhance cognitive performance, and promote A β clearance from the brain (Schenk *et al.*, 1999).

The first major active immunization trial involved AN1792, a vaccine containing full-length A β 42 peptide. Although this vaccine successfully reduced amyloid plaques and improved memory deficits in experimental studies, the clinical trial was terminated because approximately 6% of participants developed meningoencephalitis, despite showing decreased A β accumulation. Due to these safety concerns, attention shifted toward passive immunization strategies (Orgogozo *et al.*, 2003).

Passive immunization using monoclonal antibodies demonstrated several advantages, including improved antigen specificity, favorable pharmacokinetic properties, and reduced toxicity. Systemically administered monoclonal antibodies were shown to reduce circulating soluble A β through the "peripheral sink" mechanism, thereby limiting A β deposition in the brain. In addition, passive immunotherapy may directly dissolve existing A β aggregates and inhibit the formation of toxic fibrils and oligomers. As a result, numerous monoclonal antibodies are being investigated in clinical trials as potential disease-modifying therapies for AD.

A reverse translational medicine approach has also been explored, based on the isolation of naturally occurring anti-A β antibodies from cognitively healthy elderly individuals. One important example is Aducanumab, a human IgG1 monoclonal antibody that selectively targets aggregated A β . Aducanumab has demonstrated dose-dependent reduction of amyloid plaque deposition and has shown potential to slow cognitive decline in patients with AD (Sevigny *et al.*, 2016).

Based on the tau hypothesis

Apart from Amyloid- β (A β), the Tau protein is considered another major contributor to the pathogenesis of AD. The tau hypothesis proposes that abnormal aggregation of hyperphosphorylated tau leads to the formation of NFTs, one of the characteristic histopathological hallmarks of AD. Tau is a hydrophilic and intrinsically unfolded microtubule-associated protein predominantly present in neuronal cells of the brain, where it plays a critical role in maintaining microtubule stability and axonal transport. Six different isoforms of tau are expressed in the adult human brain, and their varying affinities for

microtubules influence their tendency to aggregate into NFTs. Consequently, alterations in tau gene expression and alternative splicing mechanisms have emerged as important therapeutic targets in tauopathies (Lee *et al.*, 2001; Wang and Mandelkow, 2016).

Numerous preclinical investigations have shown that pathological tau can initiate and propagate abnormal signaling cascades within neurones, thereby contributing to neurodegeneration. Under physiological conditions, tau is mainly localized in neuronal axons; however, in AD and related tauopathies, tau abnormally accumulates not only in axons but also in dendrites and neuronal cell bodies. Tau undergoes several posttranslational modifications, including phosphorylation, acetylation, glycosylation, and ubiquitination, which promote its oligomerization and aggregation (Iqbal *et al.*, 2016). Among these modifications, phosphorylation is considered the most critical event in tau pathology. Excessive phosphorylation converts tau into paired helical filaments, which subsequently aggregate to form NFTs (Ballatore *et al.*, 2007).

Hyperphosphorylated tau loses its normal affinity for microtubules, leading to destabilization of the neuronal cytoskeleton and impairment of axonal transport. These alterations ultimately contribute to neuronal dysfunction, neurodegeneration, and cell death. Because of the central role of tau hyperphosphorylation in AD progression, several therapeutic approaches have been investigated to restore microtubule stability and preserve neuronal integrity (Brunden *et al.*, 2010). These include inhibitors of tau phosphorylation, particularly kinase inhibitors targeting glycogen synthase kinase-3 β , phosphatase modulators, and microtubule-stabilizing agents. Compounds derived from paclitaxel, such as epothilone D, have shown potential because of their ability to penetrate the brain and stabilize neuronal microtubules (SantaCruz *et al.*, 2005).

In addition to targeting phosphorylation, inhibition of tau aggregation has become another important therapeutic strategy for reducing tau-associated neurotoxicity. Preventing the assembly of toxic tau oligomers and fibrils may help minimize neuronal damage and slow disease progression. Furthermore, enhancement of pathological tau clearance through immunotherapy has emerged as a promising treatment approach. Tau-directed immunotherapies aim to facilitate the removal of abnormal phosphorylated tau species and reduce NFT burden in the brain (Santa-Maria *et al.*, 2007).

CONCLUSION

Recent studies have also highlighted the role of microRNAs in regulating tau expression. miR-219 has been shown to bind to the 3' untranslated region of tau mRNA and suppress Tau protein expression. Reduced levels of miR-219 have been reported in AD, suggesting that restoration of miR-219 activity may represent

a novel therapeutic strategy for controlling tau pathology and slowing neurodegeneration (Salta and De Strooper, 2017).

ABBREVIATIONS

AD: Alzheimer's disease; **APP:** Amyloid Precursor Protein; **PSEN1:** presenilin 1; **PSEN2:** presenilin 2; **SAD:** SPORADIC ALZHEIMER'S DISEASE; **A β :** Amyloid-beta; **NMDAR:** N-methyl-D-Aspartate Receptor; **NFTs:** Neurofibrillary Tangles; **ACh:** acetylcholine; **BACE1:** β -site APP Cleaving Enzyme-1; **sAPP β :** Soluble APP- β ; **CTF99:** C-Terminal Fragment 99; **C99:** C-Terminal Fragment 99; **PS1:** Presenilin-1; **PS2:** Presenilin-2; **sAPP α :** soluble APP- α ; **C83:** C-Terminal Fragment 83; **CTF α :** C-Terminal Fragment α ; **A β DPs:** A β -degrading Proteases; **nAChR:** Nicotinic Acetylcholine Receptor; **AMPA:** α -Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid; **GSIs:** γ -Secretase Inhibitors; **IgG1:** Immunoglobulin G1; **mRNA:** Messenger RNA; **miR-219:** microRNA-219.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

REFERENCES

- Alberts, B., Johnson, A., Lewis, J. et al. (2015). Molecular biology of the cell. In *Molecular biology of the cell* (6th ed). Garland Science.
- Alzheimer's Association (2016). 2016 Alzheimer's disease facts and figures. *Alzheimer's and Dementia*, 12(4), 459-509. doi: 10.1016/j.jalz.2016.03.001, PubMed: 27570871.
- Anand, P., and Singh, B. (2013). A review on cholinesterase inhibitors for Alzheimer's disease. *Archives of Pharmacol Research*, 36(4), 375-399. doi: 10.1007/s12272-013-0036-3, PubMed: 23435942.
- Ballatore, C., Lee, V. M., and Trojanowski, J. Q. (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. *Nature Reviews Neuroscience*, 8(9), 663-672. doi: 10.1038/nrn2194, PubMed: 17684513.
- Borchelt, D. R., Davis, J., Fischer, M., Lee, M. K., Slunt, H. H., Ratovitsky, T., Price, D. L. (1996). A vector for expressing foreign genes in the brains and hearts of transgenic mice. *Genetic Analysis: Biomolecular Engineering*, 13(6), 159-163. doi: 10.1016/S1050-3862(96)00167-2, PubMed: 9117892.
- Brooks, D. J. (2012). Alzheimer's disease: Diagnosis and therapeutics. *Journal of Nuclear Medicine*, 53(3), 409-416. doi: 10.2967/jnumed.111.095141
- Brunden, K. R., Ballatore, C., Crowe, A. et al. (2010). Tau-directed drug discovery for Alzheimer's disease and related tauopathies. *Nature Reviews Drug Discovery*, 9(10), 783-793.
- Cummings, J., Lee, G., Ritter, A., and Zhong, K. (2021). Alzheimer's disease drug development pipeline. *Alzheimer's and Dementia*, 7(1), e12179.
- De Strooper, B. (2003). 1, Pen-2, and nicastrin with presenilin generate an active γ -secretase complex. *Neuron*, 38(1), 9-12. doi: 10.1016/S0896-6273(03)00205-8, PubMed: 12691659.
- De Strooper, B., and Karran, E. (2016). The cellular phase of Alzheimer's disease. *Cell*, 164(4), 603-615. doi: 10.1016/j.cell.2015.12.056, PubMed: 26871627.
- DeTure, M. A., and Dickson, D. W. (2019). The neuropathological diagnosis of Alzheimer's disease. *Molecular Neurodegeneration*, 14(1), 32. doi: 10.1186/s13024-019-0333-5, PubMed: 31375134.
- Gandy, S., and Tanzi, R. E. (2010). Alzheimer's disease therapeutic development: The path to 2025. *Alzheimer's Research and Therapy*, 2(3), 13.
- Ghosh, A. K., and Osswald, H. L. (2014). BACE1 (β -secretase) inhibitors for the treatment of Alzheimer's disease. *Chemical Society Reviews*, 43(19), 6765-6813. doi: 10.1039/C3CS60460H, PubMed: 24691405.
- Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., James, L. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*, 349(6311), 704-706. doi: 10.1038/349704a0, PubMed: 1671712.
- Haass, C., and Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β -peptide. *Nature Reviews Molecular Cell Biology*, 8(2), 101-112. doi: 10.1038/nrn2101, PubMed: 17245412.
- Hardy, J., and Allsop, D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer's disease. *Trends in Pharmacological Sciences*, 12(10), 383-388. doi: 10.1016/0165-6147(91)90609-V, PubMed: 1763432.
- Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science*, 297(5580), 353-356. doi: 10.1126/science.1072994, PubMed: 12130773.
- Hardy, J. A., and Higgins, G. A. (1992). Alzheimer's disease: The amyloid cascade hypothesis. *Science*, 256(5054), 184-185. doi: 10.1126/science.1566067, PubMed: 1566067.
- Holtzman, D. M., Herz, J., and Bu, G. (2012). Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. *Cold Spring Harbor Perspectives in Medicine*, 2(3), a006312. doi: 10.1101/cshperspect.a006312, PubMed: 22393530.
- Hook, V. Y., Kindy, M., and Hook, G. (2008). Inhibitors of cathepsin B improve memory and reduce A β in transgenic Alzheimer's disease mice expressing the wild-type, but not the Swedish mutant, β -secretase APP site. *Journal of Biological Chemistry*, 283(12), 7745-7753. doi: 10.1074/jbc.M708362200, PubMed: 18184658.
- Hynd, M. R., Scott, H. L., and Dodd, P. R. (2004). Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. *Neurochemistry International*, 45(5), 583-595. doi: 10.1016/j.neuint.2004.03.007, PubMed: 15234100.
- Iqbal, K., Liu, F., and Gong, C. X. (2016). Tau and neurodegenerative disease: The story so far. *Nature Reviews Neurology*, 12(1), 15-27. doi: 10.1038/nrn.2015.225, PubMed: 26635213.
- Kandel, E. R., Schwartz, J. H., Jessell, T. M. et al. (2013). Principles of neural science. In *Principles of neural science* (5th ed). New York: McGraw-Hill.
- Kivipelto, M., Rovio, S., Ngandu, T., Kåreholt, I., Eskelinen, M., Winblad, B., Nissinen, A. (2008). Apolipoprotein E ϵ 4 magnifies lifestyle risks for dementia: A population-based study. *Journal of Cellular and Molecular Medicine*, 12(6B), 2762-2771. doi: 10.1111/j.1582-4934.2008.00296.x, PubMed: 18318693.
- Kumar, A., Singh, A., and Ekavali, (2015). A review on Alzheimer's disease pathophysiology and its management: An update. *Pharmacological Reports*, 67(2), 195-203. doi: 10.1016/j.pharep.2014.09.004, PubMed: 25712639.
- LaFerla, F. M., and Oddo, S. (2005). Alzheimer's disease: A β , tau and synaptic dysfunction. *Trends in Molecular Medicine*, 11(4), 170-176. doi: 10.1016/j.molmed.2005.02.009, PubMed: 15823755.
- Lane, C. A., Hardy, J., and Schott, J. M. (2018). Alzheimer's disease. *European Journal of Neurology*, 25(1), 59-70. doi: 10.1111/ene.13439, PubMed: 28872215.
- Lee, V. M., Goedert, M., and Trojanowski, J. Q. (2001). Neurodegenerative tauopathies. *Annual Review of Neuroscience*, 24, 1121-1159. doi: 10.1146/annurev.neuro.24.1.1121, PubMed: 11520930.
- Levy, E., Sastre, M., Kumar, A., Gallo, G., Piccardo, P., Ghetti, B., and Tagliavini, F. (2001). Codeposition of cystatin C with amyloid- β protein in the brain of Alzheimer disease patients. *Journal of Neuropathology and Experimental Neurology*, 60(1), 94-104. doi: 10.1093/jnen/60.1.94, PubMed: 11202179.
- Mattson, M. P. (2004). Pathways towards and away from Alzheimer's disease. *Nature*, 430(7000), 631-639. doi: 10.1038/nature02621, PubMed: 15295589.
- Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., and Love, S. (2011). A β -degrading enzymes: Potential for treatment of Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*, 70(11), 944-959. doi: 10.1097/NEN.0b013e3182345e46, PubMed: 22002425.
- Orgogozo, J. M., Gilman, S., Dartigues, J. F., Laurent, B., Puel, M., Kirby, L. C., Hock, C. (2003). Subacute meningoencephalitis in a subset of patients with AD after A β 42 immunization. *Neurology*, 61(1), 46-54. doi: 10.1212/01.WNL.0000073623.84147.A8, PubMed: 12847155.
- Parsons, C. G., Danysz, W., Dekundy, A., and Pulte, I. (2013). Memantine and cholinergic based treatments for Alzheimer's disease. *Neurotoxic Research*, 24(3), 358-369. doi: 10.1007/s12640-013-9398-z, PubMed: 23657927.
- Postina, R. (2012). Activation of α -secretase cleavage. *Journal of Neurochemistry*, 120(Suppl. 1), 46-54. doi: 10.1111/j.1471-4159.2011.07459.x, PubMed: 21883223.
- Querfurth, H. W., and LaFerla, F. M. (2010). Alzheimer's disease. *New England Journal of Medicine*, 362(4), 329-344. doi: 10.1056/NEJMr0909142, PubMed: 20107219.
- Reiman, E. M. et al. (2020). Alzheimer's disease genetics and the amyloid pathway. *Nature Reviews Neurology*, 16(5), 241-256.
- Salta, E., and De Strooper, B. (2017). Non-coding RNAs in neurodegeneration. *Nature Reviews Neuroscience*, 18(10), 627-640. doi: 10.1038/nrn.2017.90;
- SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Ashe, K. H. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. *Science*, 309(5733), 476-481. doi: https://doi.org/10.1126/science.1113694, PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16020737.
- Santa-Maria, I., Hernández, F., Del Rio, J. et al. (2007). The role of GSK-3 in Alzheimer disease. *Expert Review of Neurotherapeutics*, 7(11), 1527-1533.
- Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Seubert, P. (1999). Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature*, 400(6740), 173-177. doi: 10.1038/22124, PubMed: 10408445.
- Selkoe, D. J., and Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Molecular Medicine*, 8(6), 595-608. doi: 10.15252/emmm.201606210, PubMed: 27025652.
- Sevigny, J., Chiao, P., Bussiére, T., Weinreb, P. H., Williams, L., Maier, M., Sandrock, A. (2016). The antibody aducanumab reduces A β plaques in Alzheimer's disease. *Nature*, 537(7618), 50-56. doi: 10.1038/nature19323, PubMed: 27582220.
- Suciu, R. S., and Huang, Y. (2021). Human stem cell models of Alzheimer's disease: Progress and challenges. *Neuroscience Bulletin*, 37(6), 863-882.

- Tanzi, R. E., and Bertram, L. (2005). Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. *Cell*, 120(4), 545-555. doi: 10.1016/j.cell.2005.02.008, PubMed: 15734686
- Terry, A. V., Jr., and Buccafusco, J. J. (2003). The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. *Journal of Pharmacology and Experimental Therapeutics*, 306(3), 821-827. doi: 10.1124/jpet.102.041616, PubMed: 12805474.
- Vassar, R., Kuhn, P. H., Haass, C., Kennedy, M. E., Rajendran, L., Wong, P. C., and Lichtenthaler, S. F. (2014). Function, therapeutic potential and cell biology of BACE proteases: Current status and future prospects. *Journal of Neurochemistry*, 130(1), 4-28. doi: 10.1111/jnc.12715, PubMed: 24646365.
- Wang, Y., and Mandelkow, E. (2016). Tau in physiology and pathology. *Nature Reviews. Neuroscience*, 17(1), 5-21. doi: 10.1038/nrn.2015.1, PubMed: 26631930.
- Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Zetterberg, H. (2016). Defeating Alzheimer's disease and other dementias: A priority for European science and society. *Lancet. Neurology*, 15(5), 455-532. doi: 10.1016/S1474-4422(16)00062-4, PubMed: 26987701

Cite this article: Lodhi R, Sharma VK. Role of Amyloid Beta and Tau Protein in Alzheimer's disease. *J Pharm Pract Comm Med*. 2026;12(4):202-10.